The New England journal of medicine, 2023-04, Vol.388 (16), p.1478-1490
- Hoeper, Marius M.
- Badesch, David B.
- Ghofrani, H. Ardeschir
- Gibbs, J. Simon R.
- Gomberg-Maitland, Mardi
- McLaughlin, Vallerie V.
- Preston, Ioana R.
- Souza, Rogerio
- Waxman, Aaron B.
- Grünig, Ekkehard
- Kopeć, Grzegorz
- Meyer, Gisela
- Olsson, Karen M.
- Rosenkranz, Stephan
- Xu, Yayun
- Miller, Barry
- Fowler, Marcie
- Butler, John
- Koglin, Joerg
- de Oliveira Pena, Janethe
- Humbert, Marc
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Hoeper, Marius M.
- Badesch, David B.
- Ghofrani, H. Ardeschir
- Gibbs, J. Simon R.
- Gomberg-Maitland, Mardi
- McLaughlin, Vallerie V.
- Preston, Ioana R.
- Souza, Rogerio
- Waxman, Aaron B.
- Grünig, Ekkehard
- Kopeć, Grzegorz
- Meyer, Gisela
- Olsson, Karen M.
- Rosenkranz, Stephan
- Xu, Yayun
- Miller, Barry
- Fowler, Marcie
- Butler, John
- Koglin, Joerg
- de Oliveira Pena, Janethe
- Humbert, Marc
- Titel
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- Ist Teil von
- The New England journal of medicine, 2023-04, Vol.388 (16), p.1478-1490
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In this double-blind, randomized, placebo-controlled trial, sotatercept increased the exercise capacity of patients with pulmonary arterial hypertension.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2213558Titel-ID: cdi_hal_primary_oai_HAL_hal_04498575v1
- Format
- –
- Schlagworte
- Adult, Apoptosis, Blood pressure, Body weight, Brain natriuretic peptide, Cardiology, Cardiology General, Cardiovascular Agents - administration & dosage, Cardiovascular Agents - adverse effects, Cardiovascular Agents - pharmacology, Cardiovascular Agents - therapeutic use, Clinical Medicine, Clinical Medicine General, Clinical trials, Cognitive ability, Committees, Critical Care, Critical Care General, Double-Blind Method, Emotions, Exercise Tolerance - drug effects, Functional morphology, Fusion protein, Hemodynamics, Hemoglobin, Humans, Hypertension, Hypertension, Pulmonary - drug therapy, Injections, Subcutaneous, International organizations, Life Sciences, Ligands, Morbidity, Outpatient-Based Clinical Medicine, Patients, Placebos, Pulmonary, Pulmonary Arterial Hypertension - diagnosis, Pulmonary Arterial Hypertension - drug therapy, Pulmonary arteries, Pulmonary Hypertension, Recombinant Fusion Proteins - administration & dosage, Recombinant Fusion Proteins - adverse effects, Recombinant Fusion Proteins - pharmacology, Recombinant Fusion Proteins - therapeutic use, Respiratory System Agents - administration & dosage, Respiratory System Agents - adverse effects, Respiratory System Agents - pharmacology, Respiratory System Agents - therapeutic use, Signal transduction, Thrombocytopenia, Treatment Outcome, Vascular Resistance - drug effects, Veins & arteries, Walk Test